



VIRUSURE

3rd Virus Safety Workshop

AsahiKASEI
BIOPROCESS

08:30 Registration

08:50 Welcome
(Andy Bailey, ViruSure)

General aspects of ICH Q5A (R2)

Chair: Ralf Klein (VirusSure)

09:00 Introduction to virus safety in the ICH Q5A (R2) era
(Andy Bailey, ViruSure)

09:30 Regulatory perspective on the ICHQ5A (R2)
(TBD)

10:00 *Coffee Break*

New Products

Chair: Angelika Spreitzhofer (VirusSure)

10:30 How to adapt analytical package to gene therapy constraints for rAAV products?
(Gaël Debaue, UCB)

11:00 Mycoplasma testing for cell & gene therapy products
(Jill Mariano & Lori Daane, Bionique)

11:30 Biosafety testing throughout the Alofisel manufacturing process
(Itziar Palacios López, Takeda)

12:00 Exploring the Invisible: Electron microscopy's role in safeguarding viral safety and advancing gene therapy
(Ashley Layland, NeoTEM)

12:30 *Lunch*

Platform technologies for Viral Clearance and Continuous Manufacturing

Chair: Jürgen Ebner (VirusSure)

13:30 Impact of prior knowledge on viral clearance strategies
(Katy Lorineau, ViruSure)

14:00 Adapting Virus Filtration Operation to Continuous Processing Challenges
(Roya Dayani, Asahi Kasei Bioprocess Europe)

14:30 An end2end process for continuous biomanufacturing of antibodies
(Alois Jungbauer, BOKU)

15:00 Virus safety in the plasma industry - a unique challenge
(Marcel Asper, Biotest)

15:30 *Coffee Break*

Advanced testing strategies

Chair: Andy Bailey (VirusSure)

16:00 PCR vs Infectivity Assay
(Natascha Hodosi, ViruSure)

16:30 NGS as a tool to replace traditional pathogen safety testing strategies
(Hans-Peter Fasching, ViruSure)

17:00 Rapid Identification of Adventitious Agents and the importance of Raw Material Sourcing
(Tiffany Avory, ViruSure)

17:30 *Networking drinks*

Date

8th April 2024

Location

TechGate Technology Building
Donau-City-Strasse 1
1220 Vienna, Austria

Cost

180 EUR

Contact

virussafety@virusure.com

Registration

[VirusSure 3rd Virus Safety Workshop](#)